Lilly buys migraine antibody

Share this article:

Eli Lilly announced Monday that it scooped up rights for an antibody that Phase-II data indicate may help treat recurrent migraine headaches.

Lilly had in fact discovered the molecule, LY2951742, which is a calcitonin gene-related peptide antibody, but licensed development to Arteaus Therapeutics. The development deal was an alternative risk-sharing strategy: Atlas Venture and Orbimed created Arteaus in 2011 once the antibody license was in place.

Eli Lilly said it expects Monday's deal will trigger a $57.1 million pre-tax fourth-quarter charge.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.